DS
Therapeutic Areas
Immunic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vidofludimus calcium (IMU-838) | Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 |
| IMU-856 | Crohn's Disease (CD) | Phase 1b |
| IMU-381 / IMU-935 | Oncology / Inflammatory Diseases | Preclinical |
Leadership Team at Immunic
DD
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, President, and Director
DA
Dr. Andreas Muehler, M.D.
Chief Medical Officer
DD
Dr. Duane Nash, M.D., J.D., M.B.A.
Chairman of the Board
DH
Dr. H. Daniel Perez
Board Director
DB
Dr. Barbara L. Klencke, M.D.
Board Director
DM
Dr. Monika B. Toernquist, Ph.D.
Board Director
DS
Dr. Sven Rohmann, M.D., Ph.D.
Chief Financial Officer
DW
Dr. Werner Tschollar
Head of Development
DA
Dr. Andreas Rauch, Ph.D.
Head of Research